Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
ResMed Analyst Ratings and Price Targets | NYSE:RMD | Benzinga
ResMed Inc has a consensus price target of $238.46 based on the ratings of 17 analysts. The high is $286 issued by JP Morgan on January 31, 2025. The low is $169 issued by Morgan Stanley on October 27, 2023. The 3 most-recent analyst ratings were released by Stifel, JP Morgan, and Keybanc on March 5, 2025, January 31, 2025, and January 31, 2025, respectively. With an average price target of $268.67 between Stifel, JP Morgan, and Keybanc, there's an implied 20.92% upside for ResMed Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
JP Morgan
Keybanc
Piper Sandler
RBC Capital
1calculated from analyst ratings
Analyst Ratings for ResMed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | — | Citigroup | Mathieu Chevrier14% | — | Upgrade | Neutral → Buy | Get Alert |
| 03/05/2025 | Buy Now | 8.02% | Stifel | Jonathan Block73% | $250 → $240 | Maintains | Hold | Get Alert |
| 01/31/2025 | Buy Now | 28.72% | JP Morgan | David Low47% | $270 → $286 | Maintains | Overweight | Get Alert |
| 01/31/2025 | Buy Now | 26.02% | Keybanc | Brett Fishbin51% | $266 → $280 | Maintains | Overweight | Get Alert |
| 01/31/2025 | Buy Now | 17.02% | Piper Sandler | Adam Maeder65% | $252 → $260 | Maintains | Neutral | Get Alert |
| 01/31/2025 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | Hold → Hold | Get Alert |
| 01/10/2025 | Buy Now | 13.42% | Piper Sandler | Adam Maeder65% | → $252 | Initiates | → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 12.52% | Stifel | Jonathan Block73% | → $250 | Initiates | → Hold | Get Alert |
| 10/25/2024 | Buy Now | 4.42% | RBC Capital | Craig Wong-Pan69% | $224 → $232 | Maintains | Sector Perform | Get Alert |
| 10/25/2024 | Buy Now | 19.72% | Keybanc | Brett Fishbin51% | $251 → $266 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 27.37% | Baird | Joe Vruwink68% | $280 → $283 | Maintains | Outperform | Get Alert |
| 10/25/2024 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | → Hold | Get Alert |
| 10/01/2024 | Buy Now | 0.81% | RBC Capital | Craig Wong-Pan69% | $206 → $224 | Maintains | Sector Perform | Get Alert |
| 10/01/2024 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | → Hold | Get Alert |
| 09/26/2024 | Buy Now | 21.52% | B of A Securities | Lyanne Harrison44% | $240 → $270 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 26.02% | Baird | Joe Vruwink68% | → $280 | Initiates | → Outperform | Get Alert |
| 09/18/2024 | Buy Now | — | Needham | Mike Matson57% | — | Reiterates | → Hold | Get Alert |
| 09/18/2024 | Buy Now | -18.99% | Wolfe Research | Mike Polark54% | → $180 | Downgrade | Peer Perform → Underperform | Get Alert |
| 09/04/2024 | Buy Now | 6.22% | Needham | Mike Matson57% | $236 → $236 | Downgrade | Buy → Hold | Get Alert |
| 08/02/2024 | Buy Now | -7.29% | RBC Capital | Craig Wong-Pan69% | $204 → $206 | Maintains | Sector Perform | Get Alert |
| 08/02/2024 | Buy Now | 12.97% | Keybanc | Brett Fishbin51% | $238 → $251 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 6.22% | Needham | Mike Matson57% | $236 → $236 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | -8.19% | RBC Capital | Craig Wong-Pan69% | $200 → $204 | Maintains | Sector Perform | Get Alert |
| 06/25/2024 | Buy Now | — | Oppenheimer | Suraj Kalia54% | — | Downgrade | Outperform → Perform | Get Alert |
| 06/24/2024 | Buy Now | — | Citigroup | Mathieu Chevrier14% | — | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 6.22% | Needham | Mike Matson57% | $236 → $236 | Reiterates | Buy → Buy | Get Alert |
| 04/26/2024 | Buy Now | -9.99% | Oppenheimer | Suraj Kalia54% | $205 → $200 | Maintains | Outperform | Get Alert |
| 04/26/2024 | Buy Now | -9.99% | RBC Capital | Craig Wong-Pan69% | $187 → $200 | Maintains | Sector Perform | Get Alert |
| 04/26/2024 | Buy Now | 7.12% | Keybanc | Brett Fishbin51% | $227 → $238 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | 6.22% | Needham | Mike Matson57% | $224 → $236 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 0.81% | Needham | Mike Matson57% | $215 → $224 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | -3.24% | Mizuho | Anthony Petrone65% | $215 → $215 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 2.16% | Keybanc | Brett Fishbin51% | → $227 | Initiates | → Overweight | Get Alert |
| 01/30/2024 | Buy Now | -7.74% | Oppenheimer | Suraj Kalia54% | $185 → $205 | Maintains | Outperform | Get Alert |
| 01/30/2024 | Buy Now | -3.24% | Mizuho | Anthony Petrone65% | $195 → $215 | Maintains | Buy | Get Alert |
| 01/26/2024 | Buy Now | -12.24% | Mizuho | Anthony Petrone65% | $180 → $195 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | -18.09% | RBC Capital | Craig Wong-Pan69% | $181 → $182 | Maintains | Sector Perform | Get Alert |
| 01/25/2024 | Buy Now | -18.99% | UBS | Saul Hadassin66% | $175 → $180 | Maintains | Neutral | Get Alert |
| 01/25/2024 | Buy Now | -3.24% | Needham | Mike Matson57% | $180 → $215 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -12.24% | JP Morgan | David Low47% | $160 → $195 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | -27.99% | Mizuho | Anthony Petrone65% | $180 → $160 | Maintains | Buy | Get Alert |
| 10/27/2023 | Buy Now | -23.94% | Morgan Stanley | Sean Laaman73% | → $169 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/16/2023 | Buy Now | -21.24% | Oppenheimer | Suraj Kalia54% | $275 → $175 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | -9.09% | RBC Capital | Craig Wong-Pan69% | $273 → $202 | Downgrade | Outperform → Sector Perform | Get Alert |
| 09/29/2023 | Buy Now | — | Wolfe Research | Mike Polark54% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/18/2023 | Buy Now | 3.52% | B of A Securities | Lyanne Harrison44% | $250 → $230 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -18.99% | Mizuho | Anthony Petrone65% | $255 → $180 | Maintains | Buy | Get Alert |
| 09/06/2023 | Buy Now | -18.99% | Needham | Mike Matson57% | → $180 | Upgrade | Hold → Buy | Get Alert |
| 09/05/2023 | Buy Now | -23.49% | UBS | Saul Hadassin66% | $265 → $170 | Downgrade | Buy → Neutral | Get Alert |
| 08/14/2023 | Buy Now | 22.87% | RBC Capital | Craig Wong-Pan69% | $284 → $273 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 27.82% | RBC Capital | Craig Wong-Pan69% | → $284 | Reiterates | Outperform → Outperform | Get Alert |
| 08/04/2023 | Buy Now | 12.52% | B of A Securities | Lyanne Harrison44% | $260 → $250 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 17.02% | Keybanc | Matthew Mishan53% | $280 → $260 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | 27.82% | RBC Capital | Craig Wong-Pan69% | $262 → $284 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/22/2023 | Buy Now | 30.52% | UBS | Saul Hadassin66% | → $290 | Initiates | → Buy | Get Alert |
| 04/14/2023 | Buy Now | 14.77% | Mizuho | Anthony Petrone65% | → $255 | Initiates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 14.77% | Mizuho | Anthony Petrone65% | → $255 | Initiates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 17.02% | JP Morgan | David Low47% | $245 → $260 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 10.27% | JP Morgan | David Low47% | → $245 | Upgrade | Neutral → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 14.32% | RBC Capital | Craig Wong-Pan69% | $252 → $254 | Maintains | Sector Perform | Get Alert |
| 10/28/2022 | Buy Now | 26.02% | Keybanc | Matthew Mishan53% | $276 → $280 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | 17.02% | B of A Securities | Lyanne Harrison44% | $245 → $260 | Upgrade | Neutral → Buy | Get Alert |
| 10/12/2022 | Buy Now | 10.27% | Jefferies | Matthew Taylor67% | → $245 | Initiates | → Hold | Get Alert |
| 09/08/2022 | Buy Now | — | Citigroup | John Deakin-Bell26% | — | Upgrade | Neutral → Buy | Get Alert |
| 08/12/2022 | Buy Now | — | JP Morgan | David Low47% | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/12/2022 | Buy Now | 13.42% | RBC Capital | Craig Wong-Pan69% | $246 → $252 | Downgrade | Outperform → Sector Perform | Get Alert |
| 06/15/2022 | Buy Now | 11.17% | RBC Capital | Craig Wong-Pan69% | $244 → $247 | Maintains | Outperform | Get Alert |
| 06/06/2022 | Buy Now | 9.82% | RBC Capital | Craig Wong-Pan69% | $233 → $244 | Upgrade | Sector Perform → Outperform | Get Alert |
| 04/29/2022 | Buy Now | 4.87% | RBC Capital | Craig Wong-Pan69% | $241 → $233 | Maintains | Sector Perform | Get Alert |
| 04/29/2022 | Buy Now | 24.22% | Keybanc | Matthew Mishan53% | $302 → $276 | Maintains | Overweight | Get Alert |
| 04/06/2022 | Buy Now | 26.02% | Wolfe Research | Mike Polark54% | → $280 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for ResMed (RMD) stock?
The latest price target for ResMed (NYSE:RMD) was reported by Citigroup on March 5, 2025. The analyst firm set a price target for $0.00 expecting RMD to fall to within 12 months (a possible -100.00% downside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ResMed (RMD)?
The latest analyst rating for ResMed (NYSE:RMD) was provided by Citigroup, and ResMed upgraded their buy rating.
When was the last upgrade for ResMed (RMD)?
The last upgrade for ResMed Inc happened on March 5, 2025 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for ResMed Inc.
When was the last downgrade for ResMed (RMD)?
The last downgrade for ResMed Inc happened on September 18, 2024 when Wolfe Research changed their price target from N/A to $180 for ResMed Inc.
When is the next analyst rating going to be posted or updated for ResMed (RMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating ResMed (RMD) correct?
While ratings are subjective and will change, the latest ResMed (RMD) rating was a upgraded with a price target of $0.00 to $0.00. The current price ResMed (RMD) is trading at is $222.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.